Adial Pharmaceuticals (ADIL) is a clinical-stage biopharmaceutical company with no approved products and no revenue, developing AD04 for alcohol use disorder. Under a liquidation lens as of March 31, 2026, the recovery posture is marginally positive but extremely thin and deteriorating rapidly. Total assets of $5.23M consist almost entirely of cash ($4.58M, haircut to $4.58M at 100%), prepaid expenses ($219K, nominal recovery), intangibles ($2.6K, zero recovery), and an equity method investment in Adovate LLC ($422K, carrying value but likely zero recovery in liquidation given it is a minority stake in an early-stage private entity). Total liabilities of $1.51M are entirely current—accounts payable ($574K) and accrued expenses ($937K, predominantly accrued employee compensation of $838K)—and stay at face value. On these assumptions, estimated liquidation recovery to equity is approximately $3.07M to $3.3M, materially below stated book equity of $3.72M once prepaid and the equity investment receive realistic haircuts. MFFAIS CLV of $3.07M is consistent with this estimate. The going concern opinion is active: management explicitly states cash is insufficient to fund operations for 12 months from filing, with runway estimated only into the second half of 2026. The company burned $1.61M in operating cash in Q1 2026 and the cash balance fell from $5.88M at December 31, 2025 to $4.58M at March 31, 2026—a $1.30M decrease net of $315K in ATM equity proceeds. At that gross burn rate (~$1.6M/quarter operating), remaining cash runway is approximately 6-9 months without additional financing. Accumulated deficit has grown to $92.0M from $90.0M at year-end 2025. A collaboration framework with Molteni Farmaceutici for European AD04 commercialization was announced in March 2026, but it is non-binding and has no balance-sheet impact in this period. The company also discloses a $2.3M drug manufacturing contract with approximately $1.7M remaining, cancellable by either party, which is not reflected as a liability but represents a material contingent commitment against a thin cash balance. This commitment is discussed in MD&A but is not separately tagged in XBRL.
▼ Community Notes